InvestorsHub Logo
Followers 7
Posts 365
Boards Moderated 0
Alias Born 08/12/2022

Re: None

Saturday, 08/13/2022 1:10:52 PM

Saturday, August 13, 2022 1:10:52 PM

Post# of 1456
VIDEO ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL



ZILOVERTAMAB: POTENTIALLY FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING ROR1
• Safety and efficacy results for zilovertamab + ibrutinib in patients with MCL/CLL compare favorably to historical single-
agent ibrutinib

Encouraging efficacy results in patients with p53 mutated CLL, with PFS of 100% at 24 and 30 months
• Agreement with U.S. FDA on Phase 3 global registrational study design for the treatment of patients with R/R MCL

ONCT ROR1 Expressed on Multiple:

Solid and Liquid Tumors
MCL 95%
CLL 95%
Uterus 96%
Lymphoma 90%
Prostate 90%


$ONCT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News